[Molecular mechanisms of thrombolytic therapy].
作者信息
Lijnen H R, Collen D
出版信息
Haemostasis. 1986;16 Suppl 4:3-15. doi: 10.1159/000215525.
PMID:2945768
Abstract
摘要
相似文献
1
[Molecular mechanisms of thrombolytic therapy].[溶栓治疗的分子机制]
Haemostasis. 1986;16 Suppl 4:3-15. doi: 10.1159/000215525.
2
[Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].[从分子生物化学角度看血液凝固机制：纤维蛋白溶解机制]
Rinsho Byori. 1985 Sep;33(9):982-8.
3
An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.外周和冠状动脉血栓形成的局部与全身溶栓治疗评估。
Prog Hemost Thromb. 1984;7:325-56.
4
[Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].[纤维蛋白溶解的分子机制及溶栓治疗的前景]
Vopr Med Khim. 1984 Sep-Oct;30(5):13-22.
5
[Extrinsic plasminogen activator: molecular properties and potential value as a new thrombolytic agent].[外源性纤溶酶原激活剂：分子特性及作为新型溶栓剂的潜在价值]
Verh K Acad Geneeskd Belg. 1982;44(5-6):295-305.
6
The fibrinolytic system in man.人类的纤维蛋白溶解系统。
Crit Rev Oncol Hematol. 1986;4(3):249-301. doi: 10.1016/s1040-8428(86)80014-2.
7
[Streptokinase or urokinase: the elements of choice].链激酶或尿激酶：首选药物
Haemostasis. 1986;16 Suppl 4:21-5. doi: 10.1159/000215528.
8
Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.在人工循环系统中组织型纤溶酶原激活剂、尿激酶和链激酶对血栓的溶解作用
Thromb Res. 1981 Mar 15;21(6):535-45. doi: 10.1016/0049-3848(81)90254-1.
9
Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).冠状动脉溶栓：着重于组织型纤溶酶原激活剂（t-PA）的药理学考量
Biochem Pharmacol. 1984 Jun 15;33(12):1831-8. doi: 10.1016/0006-2952(84)90536-7.
10
Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.单链尿激酶型纤溶酶原激活剂：作用机制及溶栓特性
Semin Thromb Hemost. 1987 Apr;13(2):152-9. doi: 10.1055/s-2007-1003486.
Zotero 插件